February 19, 2026

An ExoMira founder-authored study demonstrating that a natural product can inhibit USP22 and boost antitumor immunity strengthens our conviction that MIRA-1 could deliver differentiated—and potentially safer—cancer immunotherapy.

October 6, 2025

ExoMira celebrates the 2025 Nobel Prize for Treg discovery as it advances its first-in-class USP22 inhibitor, a Treg-targeted cancer immunotherapy built on this landmark biology.

September 17, 2025

ExoMira team members received AACR’s Top Poster Award for applying deep learning to characterize immune tumor ecosystems for prognostic cancer assessment.

June 4, 2025

Drs. Fang and Liu were awarded a Lurie Cancer Center Research Innovation Challenge Award to advance USP22 inhibitor development toward clinical trial readiness.

May 10, 2025

Dr. Deyu Fang moderated a leading tumor immunology session at the 2025 AAI Annual Meeting, showcasing ExoMira’s continued impact in the cancer immunotherapy space.

May 7, 2025

Dr. Huiping Liu gave an invited talk on CTC cluster plasticity and immune evasion at the 2025 FASEB Cancer Conference in Hong Kong, reinforcing ExoMira’s scientific leadership.